UniProt P12493
Gag polyprotein (P12493)
Gag polyprotein (UniProt P12493): 77 experimental structures on GenesisL1, 16 ligands bound, 82 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P12493
- Protein
- Gag polyprotein
- Experimental structures
- 77
- Predicted models
- 0
- Ligands
- 16
- Pockets
- 82 · 4 records with a druggable one
Structures
77 records of P12493 in the MolNFT archive: 77 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1GWP | Structure of the N-terminal domain of the mature HIV-1 capsid protein | solution nmr | A | — | — |
| 1GWP | Structure of the N-terminal domain of the mature HIV-1 capsid protein | solution nmr | A | — | — |
| 1HIW | Trimeric HIV-1 matrix protein | x-ray diffraction | A, B, C, Q, R, S | — | — |
| 1HIW | Trimeric HIV-1 matrix protein | x-ray diffraction | A, B, C, Q, R, S | — | — |
| 1UPH | HIV-1 Myristoylated Matrix | solution nmr | A | — | — |
| 1UPH | HIV-1 myristoylated matrix | solution nmr | A | — | — |
| 2C55 | Solution Structure of the Human Immunodeficiency Virus Type 1 p6 Protein | solution nmr | A | — | — |
| 2C55 | Solution structure of the human immunodeficiency virus type 1 P6 protein | solution nmr | A | — | — |
| 2X2D | acetyl-CypA:HIV-1 N-term capsid domain complex | x-ray diffraction | D, E | — | — |
| 2X2D | Acetyl-CYPA:HIV-1 N-term capsid domain complex | x-ray diffraction | D, E | — | — |
| 3GV2 | X-ray Structure of Hexameric HIV-1 CA | x-ray diffraction | A, B, C, D, E, F | — | — |
| 3GV2 | X-ray structure of hexameric HIV-1 ca | x-ray diffraction | A, B, C, D, E, F | — | — |
| 4U0A | Hexameric HIV-1 CA in complex with CPSF6 peptide, P6 crystal form | x-ray diffraction | A | — | — |
| 4U0A | Hexameric HIV-1 ca in complex with CPSF6 peptide, P6 crystal form | x-ray diffraction | A | — | — |
| 4U0B | Hexamer HIV-1 CA in complex with CPSF6 peptide, P212121 crystal form | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 4U0B | Hexamer HIV-1 ca in complex with CPSF6 peptide, P212121 crystal form | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 4U0C | Hexameric HIV-1 CA in complex with Nup153 peptide, P6 crystal form | x-ray diffraction | A | — | — |
| 4U0C | Hexameric HIV-1 ca in complex with NUP153 peptide, P6 crystal form | x-ray diffraction | A | — | — |
| 4U0D | Hexameric HIV-1 CA in complex with Nup153 peptide, P212121 crystal form | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 4U0D | Hexameric HIV-1 ca in complex with NUP153 peptide, P212121 crystal form | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 4U0E | Hexameric HIV-1 CA in complex with PF3450074 | x-ray diffraction | A | — | — |
| 4U0E | Hexameric HIV-1 ca in complex with PF3450074 | x-ray diffraction | A | — | — |
| 4U0F | Hexameric HIV-1 CA in Complex with BI-2 | x-ray diffraction | A | — | — |
| 4U0F | Hexameric HIV-1 ca in complex with bi-2 | x-ray diffraction | A | — | — |
| 4XFX | Structure of the native full-length HIV-1 capsid protein | x-ray diffraction | A | — | — |
| 4XFX | Structure of the native full-length HIV-1 capsid protein | x-ray diffraction | A | — | — |
| 4XFY | Structure of the native full-length dehydrated HIV-1 capsid protein | x-ray diffraction | A | — | — |
| 4XFY | Structure of the native full-length dehydrated HIV-1 capsid protein | x-ray diffraction | A | — | — |
| 4XFZ | Structure of the native full-length HIV-1 capsid protein in complex with PF-3450074 (PF74) | x-ray diffraction | A | — | — |
| 4XFZ | Structure of the native full-length HIV-1 capsid protein in complex with pf-3450074 (PF74) | x-ray diffraction | A | — | — |
| 4XRO | Disulfide stabilized HIV-1 CA hexamer 4mut (S41A, Q67H, V165I, L172I) | x-ray diffraction | A | — | — |
| 4XRO | Disulfide stabilized HIV-1 ca hexamer 4MUT (S41A, Q67H, V165I, L172I) | x-ray diffraction | A | — | — |
| 4XRQ | Disulfide stabilized HIV-1 CA hexamer 4mut (S41A, Q67H, V165I, L172I) in complex with PF-3450074 | x-ray diffraction | A | 1B0 | 1 (best 0.34) |
| 4XRQ | Disulfide stabilized HIV-1 ca hexamer 4MUT (S41A, Q67H, V165I, L172I) in complex with pf-3450074 | x-ray diffraction | A | — | — |
| 5HGL | Hexameric HIV-1 CA, open conformation | x-ray diffraction | A, B, C, D, E, F | 1B0, CL | — |
| 5HGL | Hexameric HIV-1 ca, open conformation | x-ray diffraction | A, B, C, D, E, F | — | — |
| 5HGM | Hexameric HIV-1 CA in complex with dATP | x-ray diffraction | A | DTP | — |
| 5HGM | Hexameric HIV-1 ca in complex with datp | x-ray diffraction | A | — | — |
| 5HGN | Hexameric HIV-1 CA, apo form | x-ray diffraction | A | — | — |
| 5HGN | Hexameric HIV-1 ca, apo form | x-ray diffraction | A | — | — |
| 5HGO | Hexameric HIV-1 CA R18G mutant | x-ray diffraction | A | — | — |
| 5HGO | Hexameric HIV-1 ca R18G mutant | x-ray diffraction | A | — | — |
| 5HGP | Hexameric HIV-1 CA in complex with hexacarboxybenzene | x-ray diffraction | A | BHC | — |
| 5HGP | Hexameric HIV-1 ca in complex with hexacarboxybenzene | x-ray diffraction | A | — | — |
| 5IRT | Dimerization interface of the noncrystalline HIV-1 capsid protein lattice from solid state NMR… | solid-state nmr | A, B | — | — |
| 5JPA | Hexameric HIV-1 CA H12Y mutant | x-ray diffraction | A | — | — |
| 5JPA | Hexameric HIV-1 ca H12Y mutant | x-ray diffraction | A | — | — |
| 5L93 | An atomic model of HIV-1 ca-SP1 reveals structures regulating assembly and maturation | electron microscopy | A, B, C | — | — |
| 5O2U | Llama VHH in complex with p24 | x-ray diffraction | A, C | — | 2 (best 0.47) |
| 5O2U | Llama vhh in complex with P24 | x-ray diffraction | A, C | — | — |
| 5TSV | HIV-1 CA hexamer with NUP153 peptide - R3 crystal form | x-ray diffraction | A, B | FLU | — |
| 5TSV | HIV-1 ca hexamer with NUP153 peptide - R3 crystal form | x-ray diffraction | A, B | FLU | — |
| 5TSX | HIV-1 ca hexamer with NUP153 peptide - P1 crystal form | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | FLU | — |
| 5UPW | CryoEM Structure Refinement by Integrating NMR Chemical Shifts with Molecular Dynamics Simulations | electron microscopy | A, B, C, D, E, F | — | 20 (best 0.79) |
| 5UPW | Cryoem structure refinement by integrating NMR chemical shifts with molecular dynamics simulations | electron microscopy | A, B, C, D, E, F | — | — |
| 6AYA | Structure of the native full-length HIV-1 capsid protein in complex with NUP153 peptide | x-ray diffraction | A | IOD, CL | — |
| 6BHS | HIV-1 ca hexamer in complex with IP6, hexagonal crystal form | x-ray diffraction | A | IHP | — |
| 6BHT | HIV-1 CA hexamer in complex with IP6, orthorhombic crystal form | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | IHP | — |
| 6BHT | HIV-1 ca hexamer in complex with IP6, orthorhombic crystal form | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | IHP | — |
| 6H09 | HIV capsid hexamer with IP6 ligand | x-ray diffraction | A | IHP | — |
17 records more on the page itself.
Ligands
- IHP · Inositol hexakisphosphate · in 7 records
- CL · Chloride ion · in 6 records
- IOD · Iodide ion · in 6 records
- FLU · 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-benzoic acid · in 3 records
- 1B0 · N-methyl-nalpha-[(2-methyl-1H-indol-3-yl)acetyl]-N-phenyl-L-phenylalaninamide · in 2 records
- AJ2 · 4-methylquinolin-2-ol · in 1 record
- BHC · Benzene hexacarboxylic acid · in 1 record
- DTP · 2'-deoxyadenosine 5'-triphosphate · in 1 record
- QNG · N-[(1S)-1-(3-{4-chloro-3-[(methylsulfonyl)amino]-1-(2, 2,2-trifluoroethyl)-1H-indazol-7-yl}-6-[3-methyl-3-(methylsulfonyl)but-1-yn-1-yl]pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl]-2-[(3bs,4ar)-5,5-difluoro-3-(trifluoromethyl)-3B,4,4A,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide · in 1 record
- S0I · 4-benzyl-3,4-dihydroquinoxalin-2(1H)-one · in 1 record
- WZ9 · 7-azanyl-3-(phenylmethyl)-1~{H}-benzimidazol-2-one · in 1 record
- WZX · ethyl 2-(3-oxidanylidene-2,4-dihydroquinoxalin-1-yl)ethanoate · in 1 record
- X0H · methyl 2-(2-oxidanylidene-1~{H}-quinolin-4-yl)ethanoate · in 1 record
- X0L · 4-[(4-methylphenyl)methyl]-1~{H}-quinoxaline-2,3-dione · in 1 record
- XXL · ethyl (3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetate · in 1 record
- YTG · N-(4-chlorophenyl)-nalpha-[(5-hydroxy-1H-indol-3-yl) acetyl]-N-methyl-L-phenylalaninamide · in 1 record
Experiment against prediction
- 3GV2 chain E against the predicted model P73407: TM-score 0.19, RMSD 4.26 Å
- 3GV2 chain E against the predicted model P73407: TM-score 0.19, RMSD 4.26 Å
- 3GV2 chain D against the predicted model P73407: TM-score 0.19, RMSD 4.26 Å
- 3GV2 chain D against the predicted model P73407: TM-score 0.19, RMSD 4.26 Å
- 3GV2 chain F against the predicted model P73407: TM-score 0.18, RMSD 4.31 Å
- 3GV2 chain F against the predicted model P73407: TM-score 0.18, RMSD 4.31 Å
- 3GV2 chain C against the predicted model P73407: TM-score 0.18, RMSD 4.50 Å
- 3GV2 chain C against the predicted model P73407: TM-score 0.18, RMSD 4.50 Å
- 3GV2 chain B against the predicted model P73407: TM-score 0.18, RMSD 4.48 Å
- 3GV2 chain B against the predicted model P73407: TM-score 0.18, RMSD 4.48 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.